MODEYSO is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Under the CDSCO Named Patient Program, Indian patients can legally import breast cancer drugs that are FDA-approved in other countries but not commercially marketed in India.

Brand Name: MODEYSO
Generic Name: dordaviprone capsules
Strength: Capsules: 125 mg
Manufacturer: Chimerix
Approved By: EMA, USFDA

Source Details: Patient Information.

Get access MODEYSO for diffuse midline glioma harboring Treatment through Named-Patient Import in India

IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to MODEYSO (dordaviprone) capsules for personal use. For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 |  Mr. Neeraj: +91 9811 747 774.

read more